Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation THKKF


Primary Symbol: V.THNK

Healthcare Medical Devices
Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Think Research Corporation > Q3 Earnings Call
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(194)
•••
Comment by pacer217on Nov 25, 2022 11:05am
121 Views
Post# 35128169

RE:Q3 Earnings Call

RE:Q3 Earnings CallEverything you suggest is possible, BUT, I will keep the glass more than half-full. ( no choice @ this point)

I do not think I have seen a bad quarter announced on a Monday morning from any company I  have dealt with in 40 plus years. If it is, it may a first for me.

There has been zero selling pressure in last few weeks, I see that the ASK now is @ .45.  There is zero demand from players  to buy or sell THNK. Almost zero investors are interested in this stock in 2022.
 Even had they made todays announcement on Wednesday,  the effect ( yawn) would be the same.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities